Management of Optic Neuritis with Partial Recovery

Monitoring and Surveillance

Regular ophthalmological evaluations, including visual acuity testing, visual field perimetry, funduscopy, and contrast sensitivity testing, are essential every 4-6 weeks initially to track recovery trajectory, as recommended by the American Academy of Ophthalmology 1, 2
Visual-evoked potentials (VEP) should be repeated to objectively assess optic nerve function recovery and detect subclinical bilateral involvement before it becomes clinically apparent, according to the American Academy of Neurology 1, 2
Repeat MRI of brain and orbits with contrast at 3-6 months is critical to assess for new demyelinating lesions and evaluate risk of progression to multiple sclerosis, as suggested by the National Multiple Sclerosis Society 1, 2

Patients should be monitored for development of MS, as approximately 50% of optic neuritis patients will develop CDMS within 15 years, with risk highest in those with abnormal brain MRI, according to the Multiple Sclerosis Association of America 1

The patient has already received appropriate acute treatment with IV methylprednisolone followed by oral prednisolone taper, which is the standard first-line therapy, as recommended by the American College of Rheumatology 1, 2

Plasma exchange (PLEX) should only be considered if there is severe, progressive vision loss or complete lack of response to initial steroids, not for partial recovery, as suggested by the American Society of Clinical Oncology 3, 2
Long-term immunosuppressive therapy (rituximab, mycophenolate, or azathioprine) is reserved for patients with recurrent attacks or those diagnosed with neuromyelitis optica spectrum disorder (NMOSD) or MS, according to the National Institute of Neurological Disorders and Stroke 1, 2, 4

Do not delay treatment if a relapse occurs – initiation beyond 2 weeks is associated with significantly poorer visual outcomes and increased risk of severe neurological deficit, as warned by the American Academy of Neurology 1, 2
Do not discontinue monitoring prematurely – relapses are common (50-60%) and may occur during or after steroid taper, according to the Multiple Sclerosis Foundation 1, 2

New vision loss in either eye warrants immediate repeat MRI and consideration of IV methylprednisolone, as recommended by the American Academy of Ophthalmology 1, 2
Development of other neurological symptoms (weakness, sensory changes, ataxia) suggests MS progression requiring neurology consultation, according to the American Academy of Neurology 3